Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 5Nausea 4Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Radiation Injuries 1Neoplasms 1Lung Neoplasms 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9pembrolizumab 8Laparoscopy 8Gastrectomy 8Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Ramucirumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × Olanzapine × Clear all
NCT03575637 2018-07-03

Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer

Peking University

Phase 2 Unknown
180 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡